DAPT De Escalation Strategy Calculator Ticagrelor or Prasugrel to Clopidogrel

DAPT De Escalation Strategy Ticagrelor or Prasugrel to Clopidogrel Explanation and Clinical Context This calculator helps clinicians apply the two part concept of DAPT modulation in the twenty twenty five acute coronary syndrome guideline. The guideline confirms that ticagrelor and prasugrel are preferred over clopidogrel in most patients with ACS undergoing PCI because they reduce major adverse cardiovascular events and stent thrombosis at the cost of more bleeding. It also notes that in patients with ACS undergoing PCI de escalation by switching from ticagrelor or prasugrel to clopidogrel after one month may be reasonable to reduce bleeding risk, particularly when bleeding risk is high or other safety issues arise.

De escalation can be guided or unguided. Guided de escalation uses platelet function testing or genotype assays to confirm adequate clopidogrel response and has shown either noninferiority or modest bleeding benefit compared with standard potent DAPT among patients with ACS undergoing PCI. Unguided de escalation after approximately one month of potent DAPT has also been tested and in stabilized post myocardial infarction patients reduced bleeding without an excess of ischemic events when compared with longer term potent DAPT.

These strategies are summarized and integrated in the acute coronary syndrome guideline and supported by trials such as TROPICAL ACS, TOPIC, TALOS AMI and contemporary meta analyses. At the same time the guideline highlights that patients with ACS have a sustained prothrombotic state and that extension of potent DAPT beyond one year may be reasonable in selected patients who tolerate therapy and have high ischemic risk without high bleeding risk. It also emphasizes the Academic Research Consortium criteria to define high bleeding risk and presents data from abbreviated DAPT strategies in patients with high bleeding risk after PCI.

These data show that shorter DAPT followed by single antiplatelet therapy can reduce bleeding with preserved ischemic protection in carefully selected patients, although evidence remains less robust in some subgroups. The present tool structures key clinical features that the guideline suggests should drive decisions about de escalation from ticagrelor or prasugrel to clopidogrel. It captures the time from index PCI, the presence of Academic Research Consortium high bleeding risk, the use of oral anticoagulant, recent clinically important bleeding or non tolerable side effects, recurrent ischemic events, complex PCI anatomy, and the availability of guided testing.

These items are combined into simple bleeding and ischemic driver scores and into qualitative categories that reflect whether de escalation is favored, continuation is favored, or a mixed scenario is present where shared decision making and possibly guided testing are advisable. The intention is not to replace nuanced judgment, but to bring the core messages of the twenty twenty five acute coronary syndrome guideline to the bedside in a transparent and reproducible way.